Bayer Bags a World-First Approval in China as Prostate Data Land — and the Analysts Still Can't Agree

Bayer opened the trading week with two pieces of good news from its pharmaceutical pipeline, yet the sell-side response suggested the market had already priced much of it in. On Monday, JPMorgan reiterated its "Overweight" rating with a EUR 61 price target, while Jefferies stayed at "Hold" with a EUR 46 target, according to media reports — a spread that says as much about differing growth assumptions as it does about the data themselves.

The regulatory headline came out of Beijing. China's NMPA granted marketing approval for Asundexian, to be sold under the brand name Sunharbo, to reduce stroke risk in adults following a non-cardioembolic ischemic stroke or a high-risk TIA. Bayer says the drug is the world's first approved factor XIa inhibitor. The scope matters: the green light covers China and the specific patient groups named, and implies neither approval elsewhere nor any wider use.

Two Kinds of Progress, Two Different Risk Profiles

The clinical news arrived two days earlier. On Saturday, Bayer reported positive interim results from the Phase III DASL-HiCaP trial, in which Darolutamide added to androgen deprivation therapy and radiotherapy cut the risk of metastases or death by 58% versus placebo in prostate cancer patients at high risk of recurrence. Both arms received androgen deprivation and radiotherapy. The four-year metastasis-free survival rate came in at 95% against 88%. That regimen is not yet approved.

JPMorgan's Richard Vosser read the interim data as supportive of his view that consensus expectations are too low, with the radiotherapy combination seen as a further growth driver for Nubeqa. Michael Leuchten of Jefferies called the efficacy promising but framed it as confirmation of what was already known rather than a game-changer.

The distinction between the two assets is the one investors should keep in view. Sunharbo has cleared a regulatory hurdle; Darolutamide offers a possible additional treatment avenue. Neither should be mistaken for booked revenue. The Darolutamide figures come from an interim analysis, and the approval gap applies specifically to the setting studied — treating a potential label expansion as a certainty is where the risk sits. Likewise, the "world's first" label on Sunharbo describes a regulatory milestone, not demonstrated demand or a fixed revenue contribution.

Kidney Data and a Date for the Diary

Elsewhere in the pipeline, FIND-CKD analyses on Finerenone were presented at ASN Kidney Week on Saturday, with abstract data reporting reduced proteinuria and a slower decline in kidney function across the patient groups studied.

What could shift the picture is a regulatory decision on Darolutamide in the setting studied — a positive outcome there would change its status materially from where the interim data leave it. Until then, the incremental business is best treated as an option rather than a banked contribution. For Sunharbo, the test will be whether the approval translates into commercial traction.

Bayer publishes its quarterly statement for the third quarter of 2026 on November 3, with an investor video conference scheduled the same day.